39 results
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
2 May 24
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
4:10pm
Collaboration and License Agreement with Genentech, Inc. during the first quarter of 2024.
R&D Expenses: Research and development expenses were $82.4
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
22 Feb 24
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:10pm
to the recognition of previously received milestone payments under the company’s Collaboration and License Agreement with Genentech, Inc.
R&D Expenses
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
) – Embodies The Power of Our R&D Engine Motion Based Drug Design… ...Created First Known Selective FGFR2 Strong Clinical Execution Drives Rapid Pathway
8-K
EX-99.1
vba6idcx2yw6h0p9
2 Nov 23
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:10pm
8-K
EX-99.2
iltmjgn9b
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.1
6wy29p4gra5i1
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.1
4ebsncascbd0y5
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.1
w80 ha2w6kx
4 May 23
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
4:10pm
8-K
EX-99.2
g4sy261
18 Apr 23
Regulation FD Disclosure
10:42am
8-K
EX-99.1
p1rlk 2i4dtxqz97ohqo
3 Nov 22
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:11pm
8-K
EX-99.1
9t8cq
12 Sep 22
Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023
6:05am
8-K
EX-99.1
mmdo6lzo
4 Aug 22
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
4:32pm
8-K
EX-99.1
6ujrs
5 May 22
Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
12:00am
PRE 14A
8dfeg4ca
1 Apr 22
Preliminary proxy
4:30pm
8-K
EX-99.1
d96h 0p2wuplf3szyl
24 Feb 22
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
4:13pm